FLOWER MOUND, Texas & FLINT, Mich.--(BUSINESS WIRE)--
Testing of a compact cancer-treatment technology from ProTom International, Inc. (“ProTom”) demonstrated last week that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330® Proton Therapy System at the McLaren Proton Therapy Center (“MPTC”) in Flint, Michigan.
This is the first time that ProTom has tested its compact system’s gantry beam optics design. “Measuring high beam intensities at isocenter indicates well-functioning integration among various subsystems of the Radiance 330 necessary for clinical implementation,” said Vahagn Nazaryan, Ph.D., Senior Vice President of Physics for ProTom. “We delivered beam through the gantry and nozzle in the first of three gantry treatment rooms as part of validation and verification of our technical design,” stated Dr. Nazaryan. “We are pleased that the system performed as designed and quickly achieved a dose rate sufficient for standard clinical practice.”
“We are excited by the results of successful beam transport testing through our first gantry treatment room: these results were independently reproduced by our clinical physics team,” said Sung Park, Ph.D., Chief Physicist for McLaren Cancer Institute.
Earlier in the summer, ProTom installed a new custom-designed radiofrequency quadrupole (RFQ) proton linac injector from AccSys Technology Inc. This upgrade has significantly improved accelerated proton beam intensities. The RFQ upgrade resulted in an increase in injection intensity yielding in excess of several times the number of protons per cycle accelerated in the synchrotron, with further tuning and optimization ongoing at McLaren.
“Both the ProTom and McLaren teams are to be commended for achieving this very significant result, which continues to validate that the system is performing as it was designed,” said ProTom CEO Stephen L. Spotts. “ProTom is focused on final validation and testing in order to secure all regulatory clearances necessary for clinical operation.” Spotts also noted, “It is my firm belief that our Radiance 330 system is not only the most advanced proton beam scanning system available but the most economical solution as well.“
About ProTom International, Inc.
ProTom International, Inc. is a medical device company committed to a new generation of financially viable proton radiotherapy centers that are easier to implement and equipped with advanced, compact technology. The Radiance 330 Proton therapy system makes community-based proton therapy truly accessible by reducing cost and technology barriers inherent with previous generations of equipment. To find out more about the future of proton therapy, visit us at www.protominternational.com.
About McLaren Health Care Corporation
Recognized by Verispan as one of the top Integrated Health Networks in the nation, McLaren Health Care includes more than 150 locations, 15,000 employees and over 10,000 network physicians. It includes nine wholly-owned regional hospitals: McLaren Regional Medical Center in Flint; Lapeer Regional Medical Center; Ingham Regional Medical Center and Ingham Regional Orthopedic Hospital in Lansing; Bay Regional Medical Center and Bay Special Care Hospital in Bay City; Mount Clemens Regional Medical Center in Mount Clemens; Central Michigan Community Hospital in Mt. Pleasant and POH Regional Medical Center in Pontiac. McLaren Homecare Group, an award-winning home health provider, and McLaren Health Plan, a top-rated commercial and Medicaid HMO are also a part of the system. To find out more about how we’re changing the future of health care, visit www.mclaren.org.
* The Radiance 330 Proton Therapy System has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the U.S. at this time.
Contact:
ProTom International
Stephen Sledge, 904-502-4032
ssledge@protominternational.com
or
McLaren Health Care
Kevin Tompkins, 810-342-1173
KevinTo@mclaren.org
©
Testing of a compact cancer-treatment technology from ProTom International, Inc. (“ProTom”) demonstrated last week that the system achieves its design specification: delivering high-energy protons to isocenter at a beam intensity sufficient for standard clinical practice. The ProTom technical team measured stable and reproducible performance on the Radiance 330® Proton Therapy System at the McLaren Proton Therapy Center (“MPTC”) in Flint, Michigan.
This is the first time that ProTom has tested its compact system’s gantry beam optics design. “Measuring high beam intensities at isocenter indicates well-functioning integration among various subsystems of the Radiance 330 necessary for clinical implementation,” said Vahagn Nazaryan, Ph.D., Senior Vice President of Physics for ProTom. “We delivered beam through the gantry and nozzle in the first of three gantry treatment rooms as part of validation and verification of our technical design,” stated Dr. Nazaryan. “We are pleased that the system performed as designed and quickly achieved a dose rate sufficient for standard clinical practice.”
“We are excited by the results of successful beam transport testing through our first gantry treatment room: these results were independently reproduced by our clinical physics team,” said Sung Park, Ph.D., Chief Physicist for McLaren Cancer Institute.
Earlier in the summer, ProTom installed a new custom-designed radiofrequency quadrupole (RFQ) proton linac injector from AccSys Technology Inc. This upgrade has significantly improved accelerated proton beam intensities. The RFQ upgrade resulted in an increase in injection intensity yielding in excess of several times the number of protons per cycle accelerated in the synchrotron, with further tuning and optimization ongoing at McLaren.
“Both the ProTom and McLaren teams are to be commended for achieving this very significant result, which continues to validate that the system is performing as it was designed,” said ProTom CEO Stephen L. Spotts. “ProTom is focused on final validation and testing in order to secure all regulatory clearances necessary for clinical operation.” Spotts also noted, “It is my firm belief that our Radiance 330 system is not only the most advanced proton beam scanning system available but the most economical solution as well.“
About ProTom International, Inc.
ProTom International, Inc. is a medical device company committed to a new generation of financially viable proton radiotherapy centers that are easier to implement and equipped with advanced, compact technology. The Radiance 330 Proton therapy system makes community-based proton therapy truly accessible by reducing cost and technology barriers inherent with previous generations of equipment. To find out more about the future of proton therapy, visit us at www.protominternational.com.
About McLaren Health Care Corporation
Recognized by Verispan as one of the top Integrated Health Networks in the nation, McLaren Health Care includes more than 150 locations, 15,000 employees and over 10,000 network physicians. It includes nine wholly-owned regional hospitals: McLaren Regional Medical Center in Flint; Lapeer Regional Medical Center; Ingham Regional Medical Center and Ingham Regional Orthopedic Hospital in Lansing; Bay Regional Medical Center and Bay Special Care Hospital in Bay City; Mount Clemens Regional Medical Center in Mount Clemens; Central Michigan Community Hospital in Mt. Pleasant and POH Regional Medical Center in Pontiac. McLaren Homecare Group, an award-winning home health provider, and McLaren Health Plan, a top-rated commercial and Medicaid HMO are also a part of the system. To find out more about how we’re changing the future of health care, visit www.mclaren.org.
* The Radiance 330 Proton Therapy System has not been cleared by the U.S. Food and Drug Administration (FDA) for commercial distribution in the U.S. at this time.
Contact:
ProTom International
Stephen Sledge, 904-502-4032
ssledge@protominternational.com
or
McLaren Health Care
Kevin Tompkins, 810-342-1173
KevinTo@mclaren.org
©
